Literature DB >> 9453052

Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from a human PAC1 genomic library.

E Y Krynetski1, M Y Fessing, C R Yates, D Sun, J D Schuetz, W E Evans.   

Abstract

PURPOSE: To isolate and characterize the polymorphic human thiopurine S-methyltransferase (TPMT) gene.
METHODS: The human TPMT gene was isolated by PCR screening of a phage artificial chromosome (PAC) library, using exon- and intron-specific primers, then mapped and sequenced.
RESULTS: Two separate PAC1 clones were isolated that contained the same 25 kb gene with 9 exons encompassing the entire TPMT open reading frame. Structural characterization revealed distinct differences when compared to a TPMT gene previously isolated from a chromosome 6-specific human genomic library; the 5'-flanking region (putative promoter) contains 17 additional nucleotides located at position-77 upstream from the transcription start site, in addition to several nucleotide sequence differences, and intron 8 is only 1.6 kb, 5 kb shorter than previously reported. Southern and PCR analyses of genomic DNA from 18 unrelated individuals revealed only the TPMT gene structure corresponding to the PAC clones we isolated. Analysis of the TPMT promoter activity using the 5'-terminal region confirmed transcriptional activity in human HepG2 and CCRF-CEM cells. The 5'-flank is 71% GC rich and does not contain consensus sequences for TATA box or CCAAT elements. FISH analysis demonstrated the presence of the TPMT-homologous sequence on the short arm of chromosome 6 (sublocalized to 6p22).
CONCLUSIONS: These findings establish the genomic structure of the human TPMT gene, revealing differences in the promoter and intronic sequences compared to that previously reported and providing a basis for future studies to further elucidate its biological function and regulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9453052     DOI: 10.1023/a:1012111325397

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

Review 1.  NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control.

Authors:  M J Lenardo; D Baltimore
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582

Review 2.  Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms.

Authors:  E Y Krynetski; H L Tai; C R Yates; M Y Fessing; T Loennechen; J D Schuetz; M V Relling; W E Evans
Journal:  Pharmacogenetics       Date:  1996-08

3.  DNA binding site of the growth factor-inducible protein Zif268.

Authors:  B Christy; D Nathans
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

4.  Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians.

Authors:  H L Tai; E Y Krynetski; C R Yates; T Loennechen; M Y Fessing; N F Krynetskaia; W E Evans
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

5.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

Authors:  R M Weinshilboum; S L Sladek
Journal:  Am J Hum Genet       Date:  1980-09       Impact factor: 11.025

6.  Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA.

Authors:  R Honchel; I A Aksoy; C Szumlanski; T C Wood; D M Otterness; E D Wieben; R M Weinshilboum
Journal:  Mol Pharmacol       Date:  1993-06       Impact factor: 4.436

7.  Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations.

Authors:  L Lennard; J A Van Loon; J S Lilleyman; R M Weinshilboum
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

8.  Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1.

Authors:  D Lee; C Szumlanski; J Houtman; R Honchel; K Rojas; J Overhauser; E D Wieben; R M Weinshilboum
Journal:  Drug Metab Dispos       Date:  1995-03       Impact factor: 3.922

9.  A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase.

Authors:  E Y Krynetski; J D Schuetz; A J Galpin; C H Pui; M V Relling; W E Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

10.  Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia.

Authors:  W E Evans; M Horner; Y Q Chu; D Kalwinsky; W M Roberts
Journal:  J Pediatr       Date:  1991-12       Impact factor: 4.406

View more
  4 in total

Review 1.  The thiopurines: an update.

Authors:  Sally Coulthard; Linda Hogarth
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

2.  Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age.

Authors:  Catherine Ganiere-Monteil; Yves Medard; Corinne Lejus; Béatrice Bruneau; Alain Pineau; Odile Fenneteau; Michel Bourin; Evelyne Jacqz-Aigrain
Journal:  Eur J Clin Pharmacol       Date:  2004-03-12       Impact factor: 2.953

3.  Thiopurine S-methyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs.

Authors:  Barbara Wusk; G A Kullak-Ublick; C Rammert; A von Eckardstein; M Fried; K M Rentsch
Journal:  Eur J Clin Pharmacol       Date:  2004-02-24       Impact factor: 2.953

4.  A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-thioguanine as an effective therapeutic agent for TPMT-low cancer cells.

Authors:  Inki Kim; Yeon-Sook Choi; Jae Hwi Song; Eun A Choi; Sojung Park; Eun Ji Lee; Je-Keun Rhee; Song Cheol Kim; Suhwan Chang
Journal:  Mol Oncol       Date:  2018-08-29       Impact factor: 6.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.